Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the recipient of unusually large options trading activity on Monday. Investors purchased 14,331 put options on the company. This is an increase of 557% compared to the average volume of 2,182 put options.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on the stock. HC Wainwright restated a "buy" rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a research report on Friday, November 15th. StockNews.com raised shares of Galectin Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th.
Get Our Latest Analysis on Galectin Therapeutics
Galectin Therapeutics Price Performance
NASDAQ GALT traded up $0.20 during trading hours on Monday, reaching $2.31. 700,213 shares of the company's stock traded hands, compared to its average volume of 177,658. The firm has a 50-day simple moving average of $2.59 and a 200 day simple moving average of $2.52. The firm has a market cap of $144.98 million, a PE ratio of -3.14 and a beta of 0.69. Galectin Therapeutics has a 52-week low of $1.55 and a 52-week high of $4.27.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the business. Marshall Wace LLP purchased a new stake in Galectin Therapeutics in the second quarter worth approximately $43,000. Rhumbline Advisers purchased a new position in shares of Galectin Therapeutics in the 2nd quarter worth $44,000. Gladstone Institutional Advisory LLC bought a new stake in shares of Galectin Therapeutics in the third quarter worth $60,000. Barclays PLC grew its holdings in shares of Galectin Therapeutics by 309.0% in the third quarter. Barclays PLC now owns 28,587 shares of the company's stock worth $79,000 after acquiring an additional 21,598 shares during the period. Finally, Kovitz Investment Group Partners LLC purchased a new stake in Galectin Therapeutics during the third quarter valued at $117,000. Hedge funds and other institutional investors own 11.68% of the company's stock.
About Galectin Therapeutics
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Read More
Before you consider Galectin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.
While Galectin Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
